Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

<p>Statistics from DESeq2</p>

保存先:

書誌詳細
第一著者:	Alyssa C. Flint (16676029) (author)
その他の著者:	Dana K. Mitchell (16676032) (author), Steven P. Angus (15084264) (author), Abbi E. Smith (16676035) (author), Waylan Bessler (16676038) (author), Li Jiang (16676041) (author), Henry Mang (15293185) (author), Xiaohong Li (16676044) (author), Qingbo Lu (16676047) (author), Brooke Rodriguez (16676050) (author), George E. Sandusky (16676053) (author), Andi R. Masters (16676056) (author), Chi Zhang (15084270) (author), Pengtao Dang (16676059) (author), Jenna Koenig (16676062) (author), Gary L. Johnson (15081520) (author), Weihua Shen (16676065) (author), Jiangang Liu (15018711) (author), Amit Aggarwal (16610489) (author), Gregory P. Donoho (16676068) (author), Melinda D. Willard (16676071) (author), Shripad V. Bhagwat (16676074) (author), D. Wade Clapp (16676077) (author), Steven D. Rhodes (16676080) (author)
出版事項:	2025
主題:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Cell Cycle CDKs and CDK inhibitors Chemotherapy Combination chemotherapy Gene Technologies High-throughput sequencing Preclinical Models Animal models of cancer Proteomics Rare Cancers Translational Research
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
著者:: Alyssa C. Flint (16676029)
出版事項: (2025)

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025)

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025)

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025)

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025)

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025)

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
著者:: Arun Kanakkanthara (14937731)
出版事項: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
著者:: Arun Kanakkanthara (14937731)
出版事項: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
著者:: Xiaoqing Cheng (16918496)
出版事項: (2025)

Supplementary Tables from Biallelic <i>Dicer1</i> Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of <i>DICER1</i> Syndrome–Associated Cancer
著者:: Yemin Wang (17315078)
出版事項: (2025)

Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
著者:: Aurelius Omlin (14971513)
出版事項: (2025)

Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
著者:: Aurelius Omlin (14971513)
出版事項: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
著者:: Dwight H. Owen (15034782)
出版事項: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
著者:: Dwight H. Owen (15034782)
出版事項: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
著者:: Dwight H. Owen (15034782)
出版事項: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
著者:: Dwight H. Owen (15034782)
出版事項: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
著者:: Dwight H. Owen (15034782)
出版事項: (2025)

Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
著者:: Evangeline R. Jackson (15558808)
出版事項: (2025)

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
著者:: Craig M. Goodwin (14955973)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_6r2fs8pikduihni76ormgjfulm